moxifloxacin has been researched along with lenalidomide in 2 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (lenalidomide) | Trials (lenalidomide) | Recent Studies (post-2010) (lenalidomide) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 3,532 | 725 | 2,850 |
| Protein | Taxonomy | moxifloxacin (IC50) | lenalidomide (IC50) |
|---|---|---|---|
| Bromodomain-containing protein 4 | Homo sapiens (human) | 5.19 | |
| DNA damage-binding protein 1 | Homo sapiens (human) | 1.5953 | |
| Protein cereblon | Homo sapiens (human) | 1.6572 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Assaf, MS; Chen, N; Kasserra, C; Liu, L; Palmisano, M; Reyes, J; Ye, Y; Zhou, S | 1 |
1 review(s) available for moxifloxacin and lenalidomide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for moxifloxacin and lenalidomide
| Article | Year |
|---|---|
Lenalidomide at therapeutic and supratherapeutic doses does not prolong QTc intervals in the thorough QTc study conducted in healthy men.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Aza Compounds; Cross-Over Studies; Dose-Response Relationship, Drug; Electrocardiography; Fluoroquinolones; Humans; Lenalidomide; Male; Middle Aged; Moxifloxacin; Quinolines; Thalidomide; Young Adult | 2013 |